(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 February 2008 (07.02.2008)

PCT

(10) International Publication Number
WO 2008/016729 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 38/00* (2006.01)
A61K 47/40 (2006.01)

(21) International Application Number:
PCT/US2007/067007

(22) International Filing Date: 19 April 2007 (19.04.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/821,525	4 August 2006 (04.08.2006)	US
60/825,876	15 September 2006 (15.09.2006)	US
60/868,703	5 December 2006 (05.12.2006)	US
60/894,130	9 March 2007 (09.03.2007)	US

(71) Applicant *(for all designated States except US)*: **NASTECH PHARMACEUTICAL COMPANY INC.** [US/US]; 3830 Monte Villa Parkway, Bothell, WA 98021-7266 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **COSTANTINO, Henry, R.** [US/US]; 14447 156th Avenue Ne, Woodinville, WA 98072 (US). **COHEN, Annemarie, Stoudt** [US/US]; 7638 Ne 124th Street, Kirkland, WA 98034 (US). **SILENO, Anthony, P.** [US/US]; 10 Highview Boulevard, Brookhaven Hamlet, NY 11719 (US).

(74) Agents: **KNUDSEN, Peter, J.** et al.; Nastech Pharmaceutical Company Inc., 3830 Monte Villa Parkway, Bothell, WA 98021-7266 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: COMPOSITIONS FOR INTRANASAL DELIVERY OF HUMAN INSULIN AND USES THEREOF



(57) Abstract: What is described is a pharmaceutical formulation for intranasal delivery of insulin to a patient, comprising an aqueous mixture of human insulin, a solubilizing agent, a surface active agent, and a thickening agent, wherein said formulation provides a ultra-rapid acting profile to regular human insulin.

WO 2008/016729 A1

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *of inventorship (Rule 4.17(iv))*
— *as to non-prejudicial disclosures or exceptions to lack of novelty (Rule 4.17(v))*

Published:

— *with international search report*